Treating multiple sclerosis with monoclonal antibodies: a 2013 update

@article{Dei2013TreatingMS,
  title={Treating multiple sclerosis with monoclonal antibodies: a 2013 update},
  author={Annika Dei{\ss} and Isabel Brecht and Axel Haarmann and Mathias Buttmann},
  journal={Expert Review of Neurotherapeutics},
  year={2013},
  volume={13},
  pages={313 - 335}
}
The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with monoclonal antibodies covers the years 2010–2012. The natalizumab section gives a progressive multifocal leukoencephalopathy update, focusing on clinically relevant aspects. Furthermore, it outlines problems around natalizumab cessation and current evidence on therapeutic strategies thereafter. Finally, it reviews evidence on Janus-faced modes of natalizumab action besides anti-inflammatory effects… Expand
Novel therapeutic options for multiple sclerosis
TLDR
The innovative drugs recently registered and those in clinical development for MS are reviewed, with a focus on biologics, and notably, monoclonal antibodies are still well represented in the development pipelines. Expand
A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis
TLDR
Daclizumab has been observed to have multiple (biological) effects, which may contribute to beneficial effects in immune-related disease and particularly in relapsing-remitting MS. Expand
Alemtuzumab in the treatment of multiple sclerosis
TLDR
Overall, alemtuzumab is likely to be a valuable addition to the neurologist’s armamentarium for the treatment of relapsing-remitting MS. Expand
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
TLDR
Memory B cells were augmented by B cell activating factor (atacicept) and tumor necrosis factor (infliximab) blockade that are known to worsen MS, creating a unifying concept centered on memory B cells that is consistent with therapeutic, histopathological and etiological aspects of MS. Expand
Assessing risks of multiple sclerosis therapies
TLDR
The available data on safety profiles of available MS therapies are summarized while focusing mostly on serious medication specific potential adverse events without discussing the teratogenic potential of each agent (unless there is a black box warning) or hypersensitivity reactions. Expand
Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups.
TLDR
The results suggest that treatment with IFN and GA has a more pronounced influence on the B cell system of MS. Expand
[Multiple sclerosis: current immunological aspects].
TLDR
The immune reaction main components and neurodegeneration present in multiple sclerosis are analyzed, as well as the inflammatory cascade associated with demyelination. Expand
Interleukin-17 in systemic lupus erythematosus: A comprehensive review
TLDR
Current progress in IL-17A and SLE is reviewed and summarized from in vitro studies, human expression studies, and animal models, providing novel insight into its therapeutic potential. Expand
Esclerosis múltiple: aspectos inmunológicos actuales
TLDR
The immune reaction main components and neurodegeneration present in multiple sclerosis are analyzed, as well as the inflammatory cascade associated with demyelination. Expand
Multiple sclerosis treatment and infectious issues: update 2013
TLDR
This work updates the existing warning notices and infectious issues which have to be considered using drugs for multiple sclerosis and discusses the disease‐modifying therapies (DMT) which go along with threats of specific severe infections or complications. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 160 REFERENCES
Treating multiple sclerosis with monoclonal antibodies: a 2010 update
  • M. Buttmann
  • Medicine
  • Expert review of neurotherapeutics
  • 2010
TLDR
The natalizumab section of the article centers around progressive multifocal leukoencephalopathy (PML), and discusses PML risk in relation to treatment duration, bioassays for individual risk prediction, the concept of drug holidays, clinical course and treatment of PML, as well as safety-related regulatory actions. Expand
Treating multiple sclerosis with monoclonal antibodies
TLDR
This review provides a critical discussion of clinical MS trials, including protocols and interim analyses of trials currently underway, and develops a scenario for how each of the four mAbs might evolve into the market of MS therapeutics within the coming years. Expand
Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis
TLDR
Criteria to anticipate the position of monoclonal antibodies in the diversifying armamentarium of MS therapy in the coming years is discussed and specific molecular targets, clinical efficacy and safety of these compounds are discussed. Expand
Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.
TLDR
It is shown that the expansion of regulatory natural killer cells, which express high levels of the marker CD56, appears to be the most important biological effect of CD25 blockade and is one of the most promising upcoming treatments of RR-MS and possibly also other autoimmune conditions. Expand
Treatment of multiple sclerosis with anti-CD20 antibodies.
TLDR
The focus will be to review results that have emerged over the last few years from clinical trials of different anti-CD20 mAbs in patients with MS, and to consider the biological basis underlying the apparent therapeutic efficacy of B cell depletion in MS. Expand
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
TLDR
Alemtuzumab-treatment of MS patients with relapsing-remitting forms of the disease significantly reduced the risk of relapse and accumulation of disability compared to interferon β-1a treatment in a phase II trial, and Interestingly, further analysis together with parallel experimental studies suggested that alemtzumab not only reduces disease activity due to its immune cell-depleting effect, but also confers neuroprotective effects. Expand
The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis
TLDR
Until a complete, long-term safety profile of RTX is available, it cannot be considered safe with regard to the incidence of infectious complications, and the role this plays in the occurrence of infections is focused on. Expand
Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
TLDR
In one Phase II and two Phase III trials, alemtuzumab reduced the number of clinical relapses versus the active comparator, subcutaneous IFN-β-1a, in treatment-naive and treatment-experienced participants with relapsing-remitting multiple sclerosis. Expand
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
TLDR
The clinical analyses and laboratory findings support the interpretation that improvement in disability after alemtuzumab may result, in part, from neuroprotection associated with increased lymphocytic delivery of neurotrophins to the central nervous system. Expand
Treating multiple sclerosis with natalizumab
TLDR
An overview of the most relevant results from the Phase I–IV studies on natalizumab is provided and the challenges addressed to minimize and manage its adverse events in clinical practice are highlighted. Expand
...
1
2
3
4
5
...